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Abstract
Background: HIV infection is associated with a higher incidence of precancerous cervical lesions and their
progression to invasive cervical cancer (ICC). Zambia is a global epicenter of HIV and ICC, yet the overall burden
of cervical pre-cancer [cervical intraepithelial neoplasia 3 (CIN3)] and ICC among its HIV positive adult female
population is unknown. The objective of this study was to determine the burden of cervical disease among HIV
positive women in Zambia by estimating the number with CIN3 and ICC.
Methods: We conducted a cross-sectional study among 309 HIV positive women attending screening in Lusaka
(Zambia’s most populated province) to measure the cervical disease burden by visual inspection with acetic acid
enhanced by digital cervicography (DC), cytology, and histology. We then used estimates of the prevalence of CIN3
and ICC from the cross-sectional study and Spectrum model-based estimates for HIV infection among Zambian
women to estimate the burden of CIN3 and ICC among HIV positive women nationally.
Results: Over half (52 %) of the study participants screened positive by DC, while 45 % had cytologic evidence of
high grade squamous intraepithelial lesions (SIL) or worse. Histopathologic evaluation revealed that 20 % of women
had evidence of CIN2 or worse, 11 % had CIN3 or worse, and 2 % had ICC. Using the Spectrum model, we
therefore estimate that 34,051 HIV positive women in Zambia have CIN3 and 7,297 have ICC.
Conclusions: The DC, cytology, and histology results revealed a large cervical disease burden in this previously
unscreened HIV positive population. This very large burden indicates that continued scale-up of cervical cancer
screening and treatment is urgently needed.
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Background
Invasive cervical cancer (ICC) is among the most common
cancers worldwide, accounting for an estimated 270,000
deaths annually [1]. Cervical cancer is the most common
cause of cancer death among women in sub-Saharan
Africa [2], and Zambia has the second-highest inci-
dence rate of ICC in the world [1]. Sub-Saharan African
countries are also home to the majority of HIV infec-
tions, accounting for 71 % of the people living with
HIV worldwide [3]. In Zambia, the HIV prevalence in
adults was estimated at 13 % in 2012 [3], and there are
an estimated 375,000 women aged 20–44 with HIV.
HIV compounds the ICC burden, because HIV is associ-
ated with a higher prevalence of persistent infection with
high-risk human papillomavirus (HPV) – an obligate
cause of ICC [4–6]. HIV infection is also associated with a
higher incidence of precancerous cervical lesions and
accelerated progression of these lesions to ICC [7]. The
effect of antiretroviral therapy (ART) on the natural
history of cervical precancerous lesions is unclear [7], with
some studies showing no effect and other studies showing
a modest beneficial effect of ART [8, 9].
The prevalence of cervical pre-cancer and cancer is re-
ported to be high among HIV positive women in sub-
Saharan Africa. The prevalence of cervical squamous
intraepithelial lesions (SIL) among HIV positive women
in Nigeria was 13 % [10], SIL was detected in 43.5 % of
HIV positive women initiating ART in Cameroon [11],
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and pre-cancerous lesions (CIN1 or worse) were de-
tected in 27 % of HIV positive women attending an ART
clinic in Kenya [12]. A study among HIV positive
women initiating ART in South Africa reported that
66 % of women had an abnormal Pap smear, including
40 % with LSIL and 10 % with HSIL [13]. A 2005 report
from Zambia by this group described the prevalence of
SIL in HIV positive women, and found a prevalence of
53 % for high-grade SIL and worse, one of the highest
reported in any population [14]. However, the overall
disease burden of histologically-proven cervical pre-
cancer [(cervical intraepithelial neoplasia 3 (CIN3)] and
ICC in HIV positive women in Zambia is unknown.
Herein we extend our initial findings [14] by conduct-
ing a cross-sectional study of twice as many HIV positive
women in Lusaka as the 2005 study, and assess cervical
disease by DC, cytology, and histology. We compared
the women in the cross-sectional study with women
enrolled in the Cervical Cancer Prevention Program in
Zambia, and used the prevalence of CIN3 and ICC from
the cross-sectional study to estimate the disease burden
of CIN3 and ICC among HIV positive women nationally
in Zambia. The objective of this study was to provide
modeled estimates of the number of HIV positive
women in Zambia with CIN3 and ICC.
Methods
Cervical Cancer Prevention Program in Zambia
In response to the high burden of cervical SIL in HIV
positive women in Lusaka that was found in initial studies
[14], the Cervical Cancer Prevention Program in Zambia
(CCPPZ) was established in 2006. CCPPZ provides ser-
vices through the Zambian public sector platform and is
integrated into the existing HIV/AIDS care and treatment
infrastructure. The program offers visual inspection with
acetic acid enhanced by digital cervicography (DC) with
same-day cryotherapy or cold coagulation for eligible pre-
cancerous lesions, or referral for loop electrosurgical exci-
sion procedure (LEEP) or punch biopsy for ineligible
lesions [15–17]. CCPPZ originally provided services to
HIV positive women, but in response to overwhelming de-
mand, services were made available to all women by mid-
2006, regardless of HIV status. To date, CCPPZ has
screened more than 180,000 women and has scaled up
services to all provinces in Zambia. The CCPPZ clinical
database includes the years 2006–2013 and contains
individual-level information on women screened at 12
public clinics in the Lusaka area. Data is entered by nurses
into Access databases at the time of screening and is
maintained by the CCPPZ program.
Cross-sectional study
Between February 2008 and December 2011, we enrolled
309 HIV positive women aged 20–45 into a cross-sectional
screening study at Matero public health clinic in Lusaka,
Zambia. This clinic serves the Matero community, and
approximately 1500 women at the clinic are screened
for cervical cancer each year through CCPPZ. During
the study period, women were identified in the HIV
Care and Treatment clinic, where they were made
aware of cervical cancer screening and invited to attend
the cervical cancer prevention clinic. All HIV positive
women attending the clinic were invited to participate
in the study. At the cervical cancer prevention clinic, a
nurse provider counseled patients on cervical cancer
screening and the research protocol for this project,
and obtained informed consent from women willing to
participate in the study. The inclusion criteria were be-
ing HIV positive, non-pregnant by self-report, between
20–45 years of age, and healthy enough to undergo a
pelvic examination. Following written informed consent,
demographic information was collected. ART status was
by self-report: ART-naïve was defined as never having re-
ceived ART, while ART-experienced women were either
currently or previously on ART. This was the first cervical
cancer screening visit for each woman. All women were
then screened with cytology and DC as part of a cross-
sectional study to compare the test characteristics of cy-
tology to DC [18]. Trained, experienced nurses performed
all study procedures.
Pap smears were obtained using a wire brush for
sampling of the endocervix, and an Ayres plastic spat-
ula for sampling of the ectocervix. The specimens were
placed in liquid solution provided by Cytyc Corporation
(Marlborough, MA, USA) and stored at the clinic before
being batched-shipped to Cytyc every 2 weeks for immedi-
ate processing, analysis and interpretation by a senior,
board certified cytologist, according to Bethesda (2001)
nomenclature. A total of 10 % of all negative tests and
10 % of all positive tests were re-screened by a senior cyto-
pathologist for purposes of quality assurance.
Immediately after performing the Pap smear, the nurse
placed 3–5 % acetic acid on the cervix for 3 min and per-
formed VIA and DC. To obtain the digital cervicographs,
a hand-held commercial brand digital camera was used to
take a photo of the entire cervix. The image was then
magnified to facilitate assessment of acetowhite lesions.
All women also received a DC-directed biopsy with a
2 × 4 mm tip Tischler biopsy forceps. This included a
biopsy of the lesion that appeared to have the most ad-
vanced degree of neoplasia (such as prominent and
opaque acetowhite lesions with sharp borders, coarse
punctuations, or atypical blood vessels), as well as a bi-
opsy of a normal appearing area of the transformation
zone of the cervix. If the cervix had no abnormal area,
only a normal area biopsy within the transformation
zone was taken; conversely, if the cervix had no normal
area, only an abnormal area biopsy was taken. Biopsy
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specimens were immediately placed in 10 % formalin
and sent to a local pathology laboratory for histopatho-
logic analysis. A combined histology variable was cre-
ated to represent the most severe diagnosis from the
normal and abnormal areas for each woman. Women
with confirmed ICC were referred to a specialist hos-
pital in Lusaka for surgery or radiation.
The number of women enrolled into the study was
sufficient to give a reasonable estimate of CIN3+. With
an expected frequency of 10 %, confidence limits of 5 %,
and a 99 % confidence level, the sample size needed is
239 women.
Number of HIV positive women in Zambia
To estimate the number of HIV positive women aged
20–44 in Zambia, we used the AIDS Impact Module of
Spectrum model v.5.03, produced by the Futures Insti-
tute (available at: http://www.futuresinstitute.org/spec-
trum.aspx, accessed April 30, 2014). The AIDS Impact
Module projects the number of people living with HIV,
new HIV infections, and many other estimates related to
the impact of AIDS. Using default Spectrum settings
(i.e., generalized epidemic pattern and unchanged fema-
le:male incidence ratio), we obtained estimates for the
overall number of HIV positive women aged 20–44 in
2013, including stratifications according to antiretroviral
therapy (ART) status.
Prevalence-based model
We constructed a static, prevalence-based model to es-
timate the number of HIV positive women with CIN3
or ICC in Zambia. The number of HIV positive women
in Zambia with CIN3 or ICC was calculated by multi-
plying the point prevalence of these conditions, based
on histology results, from our cross-sectional study by
the number of HIV positive women aged 20–44 estimated
by Spectrum. To explore the impact of changes in assump-
tions, we performed several sensitivity analyses. These in-
cluded using the lower and upper 95 % confidence intervals
bounds of CIN3 and ICC prevalence (calculated using the
Wilson score method without continuity correction) and
adjusting the estimate of HIV positive women with CIN3
or ICC by stratifying by ART status.
Data analysis
Data cleaning and analysis was conducted using OpenEpi
Epidemiologic Calculator (www.openepi.com), Microsoft
Excel (Microsoft Corporation, Redmond, WA, USA),
and SAS™ version 9.2 (SAS Institute Inc., Cary, NC,
USA). p < 0.05 was considered statistically significant.
Ethics statement
The cross-sectional study was approved by the University
of Zambia Biomedical Research Ethics Committee on 12
December 2007 (reference number: 008-002-07) and by
the University of Alabama at Birmingham Institutional
Review Board on 27 June 2007 (registration number:
IRB00000726).
Results
Demographic data
We compared demographic characteristics between the
women from our cross-sectional study and all HIV
positive women who have been screened through the
CCPPZ in Lusaka (Table 1). Age, marital status, num-
ber of lifetime partners, previous Pap smear screening,
age at sexual debut, and gravidity were all very similar.
Although significant differences were found in age, pre-
vious Pap smear, and gravidity, the significance is likely
due to the large number of women in the CCPPZ data-
base, and these differences do not appear clinically rele-
vant. Compared with HIV positive women screened
through the CCPPZ, women from our cross-sectional
study tended to be poorer, less educated, and less likely
to work in the formal or informal sectors. In addition,
women in the cross-sectional study were more likely to
be ARV-experienced than women in the CCPPZ
database.
Test results
During DC, the study personnel performed DC-di-
rected biopsy of normal and/or abnormal appearing
areas of the cervix. The DC, liquid cytology, and hist-
ology results revealed a large cervical disease burden in
this previously unscreened HIV positive population of
women. Over half (52 %; 161) of the study participants
screened positive by DC, while 45 % (138) had cytologic
evidence of high grade SIL or worse (HSIL+) (Fig. 1).
Histopathologic evaluation revealed that one out of
every five (63; 20 %) had evidence of CIN2+ (specifically,
9.4 % had CIN2, 9.1 % had CIN3, and 1.9 % had invasive
cancer) (Fig. 1).
Number of HIV positive women with CIN3 and ICC in
Zambia
We used a simple model to estimate the burden of
cervical pre-cancer and cancer throughout Zambia.
The prevalence of CIN3 in our cross-sectional study
of HIV positive women was 9.1 % and the ICC preva-
lence was 1.9 % (Table 2). The prevalence of both
CIN3 and ICC was higher in ART-naïve women than
ART-experienced women (Table 2), although this
trend was not significant. Using the default parameters
of the Spectrum AIDS Impact Module, a total of
375,774 women aged 20–44 are estimated to be HIV
positive in Zambia.
In the base case scenario, we estimated that there are
34,051 HIV positive women with CIN3 in Zambia (Fig. 2).
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Using the lower and upper 95 % confidence intervals of
CIN3 prevalence from the cross-sectional study, the es-
timates ranged from 23,824 to 48,024 women, and
adjusting the number of HIV positive women with
CIN3 by ART status (by stratifying by ART status)
yielded an estimate of 44,576. The ART-adjusted esti-
mate is higher than the base case because there is a
higher prevalence of CIN3 in ART-naïve women
(Table 2) and a higher proportion of ART-naïve women
from the Spectrum model than in our cross-sectional
study in Lusaka. In the base case scenario, we estimated
that there are 7,297 HIV positive women with ICC in
Zambia (Fig. 2). The other ICC estimates follow a simi-
lar pattern to the CIN3 scenarios, with wide 95 % con-
fidence intervals because of small numbers of women
with ICC.
Discussion
We report a very high burden of cervical neoplasia
among a group of previously unscreened HIV positive
women, whether measured by DC, cytology, or hist-
ology. Half screened positive by DC, almost half had
HSIL+ on cytology, and one in five was diagnosed with
CIN2+ on histopathologic evaluation. Our cytology re-
sults are consistent with the previous study by this group
[14], which reported an HSIL+ prevalence of 53 %. In
addition, in the current study we found that one in four
women had low-grade squamous intraepithelial lesions
(LSIL), leading to 70 % of women having LSIL+. Across
Zambia, the CIN3 and ICC disease burden among HIV
positive women is substantial: we estimate that among
the 375,774 HIV positive women in Zambia, 34,051 have
CIN3 and 7,297 have invasive cervical cancer.
Table 1 Demographics of HIV positive women enrolled in the cross-sectional study and in the CCPPZ database
Variable HIV+ women in cross-sectional study (n = 309) HIV+ women in CCPPZ databasea (n = 26,993) p-valueb
Age (years) 306 20,031 <0.001
Median, IQR 32.0 (27.0, 37.0) 35.0 (29.0, 40.0)
Education 308 20,692 <0.001
Less than high school 275 (89.3 %) 15,425 (74.5 %)
High school completed 33 (10.7 %) 5,267 (25.5 %)
Marital status 154 16,212 0.54
Not married 59 (38.3 %) 6,605 (40.7 %)
Married 95 (61.7 %) 9,607 (59.3 %)
Employment 307 19,736 <0.001
Not employed outside the home 93 (30.3 %) 6,093 (30.9 %)
Formal sector 38 (12.4 %) 4,106 (20.8 %)
Informal sector 85 (27.7 %) 7,291 (36.9 %)
Other 91 (29.6 %) 2,246 (11.4 %)
Monthly household income 306 20,121 <0.001
Less than ZMW 500 209 (68.3 %) 9,770 (48.6 %)
ZMW 500 or more 97 (31.7 %) 10,351 (51.4 %)
Number of lifetime partners 304 25,312 0.36
Median, IQR 3.0 (2.0, 4.0) 3.0 (2.0, 4.0)
Pap smear 306 25,278 0.01
Never 306 (100 %) 24,787 (98.1 %)
Ever 0 (0 %) 491 (1.9 %)
Age at sexual debut (years) 309 25,303 0.81
Median, IQR 18.0 (16.0, 19.0) 17.0 (16.0, 19.0)
Gravidity 294 24,247 0.01
Median, IQR 3.0 (2.0, 4.0) 3.0 (2.0, 5.0)
ARV status 284 22,896 <0.001
ARV-naïve 41 (14.4 %) 6,175 (27.0 %)
ARV-experienced 243 (85.6 %) 16,721 (73.0 %)
aas of December 2013
bBy 2-tailed χ2 test or 2-tailed Wilcoxon two-sample test, as appropriate
CCPPZ, Cervical Cancer Prevention Program in Zambia
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Our 70 % prevalence of LSIL+ is extremely high, even
by sub-Saharan African standards. It is much higher
than that reported in Nigeria [10], and somewhat higher
than results from Cameroon [11] and the 50 % reported
in South Africa [13]. Likewise, the burden as measured
by histology in our study is higher than a report from
Kenya, which detected CIN1 and above in 27 % of HIV
positive women attending an ART visit [12].
A strength of our study is the use of three distinct
measurements of cervical disease: DC, cytology, and
histology. All three demonstrated a large cervical disease
burden in this population. Other strengths are the hist-
ology results on which our prevalence estimates are
based: all women received a histology diagnosis, and we
obtained histology results from both normal and
abnormal-appearing areas of the cervix. These aspects
mean that our CIN3 and ICC prevalence estimates are
not underestimated by only having a histology diagnosis
for women who screened positive, and that the preva-
lence estimates are not underestimated by only sampling
abnormal-appearing areas [19, 20].
We note several limitations to our analysis. First, there
is a relatively small sample size in the cross-sectional
study on which our prevalence estimates are based, in-
cluding the number of ART-naïve women, which leads
to relatively large confidence intervals. Second, in our
static model we could not account for inputs that
change over time, such as changes in HIV prevalence or
CIN3 or ICC prevalence. Dynamic modeling could ac-
count for these changes and other aspects, such as new
disease or recurring disease after treatment. However, an
advantage of our model is that it is straightforward to
understand and provides useful information to policy-
makers on the number of HIV positive women with
CIN3 and ICC who require cervical cancer screening
and treatment. A third weakness is that, compared with
HIV positive women screened through the CCPPZ,
women from our cross-sectional study tended to be
poorer, less educated, and be less likely to work in the
formal or informal sector. Thus, our study population is
not entirely representative of all of the women screened
through the CCPPZ. However, we performed logistic
regression to identify possible demographic variables
associated with disease, and found that none of the
Fig. 1 Cervical disease burden by digital cervicography, cytology, and
histology. We observed a large cervical disease burden by digital
cervicography (52 % positive), cytology (70 % low-grade squamous
intraepithelial lesions or worse), and histology (20 % cervical
intraepithelial neoplasia 2 or worse). Abbreviations: ASCUS, atypical
squamous cells of undetermined significance; ASC-H, atypical
squamous cells-cannot exclude HSIL; LSIL, low-grade squamous
intraepithelial lesions; HSIL, high-grade squamous intraepithelial
lesions; CIN, cervical intraepithelial neoplasia
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demographics were significantly associated with CIN2+
or CIN3+ (data not shown). This agrees with the previ-
ous study by this group [14] where we found that no
demographic variables were associated with cytology
results in HIV positive women. Thus, the demographic
differences between our cross-sectional study and
women screened through the CCPPZ are not likely to
substantially influence the prevalence estimates of
CIN3 and ICC, although the sample size of this study
may have limited the power to detect associations be-
tween demographic variables and disease.
The very large burden of cervical disease in HIV posi-
tive women reported here necessitates a multi-pronged
prevention and control approach, including primary pre-
vention with vaccination, secondary prevention with
screening and treatment of precancerous lesions, and
treatment of cervical cancers. This group has previously
reported that approximately 70 % of cervical cancers at
the University Teaching Hospital in Lusaka are positive
for HPV-16 and/or HPV-18, the two HR-HPV genotypes
in widely available vaccines [21]. In addition, immune
responses to HPV vaccination among HIV positive
women are reported to be generally robust [22]. Taken
together, these data indicate that if widely used, HPV
vaccination can play an important role in preventing cer-
vical pre-cancer and cancer in HIV positive women in
Zambia in the medium- to long-term.
Affordable screening for cervical cancer is feasible and
effective in developing countries [23], and due to the
large cervical burden, HIV positive women should be a
main focus for screening programs. In 2008, less than
15 % of Zambian women have ever had a pelvic exam
[24]. CCPPZ currently includes 33 screening clinics and
22 LEEP clinics; an expansion is planned to include 100
additional screening clinics by December 2016 (G. Parham,
personal communication). The current capacity and future
expansion of CCPPZ will allow ever-increasing num-
bers of women access to screening and treatment.
However, based on our estimates there is a very large
burden of CIN3 and ICC in HIV positive women in
Zambia, which requires further expanded support for
cervical cancer control from both local stakeholders
(such as local government and private companies) and
external funders, to maintain the current momentum
and continue to radically expand across Zambia, to en-
sure that all HIV positive women in Zambia have ac-
cess to cervical cancer screening and treatment. Much
greater access to prevention services is needed, with
the understanding that they must be sustainable for
their impact to endure. Involvement of influential compo-
nents of civil society (for example, traditional healers, trad-
itional marriage counselors, tribal chiefs and chieftainesses)
in the process of community education are warranted to
Table 2 Prevalence of CIN3 and ICC in HIV positive women
accessing cervical cancer screening in Lusaka
CIN3 ICC
Total n Prevalence
(95 % CI)
n Prevalence
(95 % CI)
Overall 309 28 9.1 (6.3, 12.8) 6 1.9 (0.9, 4.2)
ART status
ART-naïvea 41 7 17.1 (8.5, 31.3) 1 2.4 (0.4, 12.6)
ART-experienced 243 18 7.4 (4.7, 11.4) 4 1.6 (0.6, 4.2)
Unknown 25 3 12.0 (4.2, 30.0) 1 4.0 (0.7, 20.0)
aThe prevalence of CIN3 and ICC is not statistically different between ART-naïve
women and ART-experienced women
95 % CI, 95 % confidence interval; ART, antiretroviral therapy; CIN, cervical
intraepithelial neoplasia; ICC, invasive cervical cancer
Fig. 2 Estimated number of HIV positive women aged 20–44 with cervical intraepithelial neoplasia 3 (CIN3) and invasive cervical cancer (ICC) in
Zambia. Among HIV positive women, approximately 34,000 have CIN3 and 7,300 have ICC in the base case scenario. When adjusted for ART status, the
estimated numbers of women with CIN and ICC increase. Bars depict 95 % confidence intervals. Abbreviations: ART, antiretroviral treatment
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extend cancer prevention messages deeper into the com-
munity [25].
Due to late presentation and lack of access to effective
treatment, survival from cervical cancer in Africa is poor
[26]. Therefore, education to increase awareness of cer-
vical cancer screening and treatment, along with increased
availability of radiation, chemotherapy, and surgical oncol-
ogy treatment, should also be a priority.
Integrated cervical cancer prevention, screening, and
treatment in Africa is possible; Rwanda has successfully
implemented this, and has also integrated these services
into routine women’s health services [27]. Pairing cer-
vical cancer prevention, screening, and treatment with
other programs such as HIV screening or treatment pro-
grams should lead to improved access to cervical cancer
services for HIV positive women in Zambia. Political
will, partnerships, and monitoring and evaluation are all
needed for this to be successful, but with expanded sup-
port for cervical cancer control and adequate planning,
high quality service integration can be achieved [27].
Conclusions
Using DC, cytology, and histologic evaluation of both
abnormal and normal appearing areas of the cervix, we
have demonstrated the large burden of high-grade cer-
vical neoplasia among previously unscreened HIV
positive women in Zambia. The planned expansion of
CCPPZ will allow ever-increasing numbers of women
to access screening and treatment services; however,
the commitment of both local stakeholders and exter-
nal funders should be rapidly expanded to address the
large burden of disease. In light of recent strategies
aimed at exponentially accelerating access to ARV’s in
sub-Saharan Africa (e.g., Option B+), it is imperative
that simultaneous investments are made in scaling up
cervical cancer prevention services for this very high
risk population, to prevent the tragedy of HIV positive
women living long enough to develop and die from
invasive cervical cancer. An integrated cervical cancer
prevention, screening, and treatment approach is
needed, and pairing this with ongoing HIV programs
should lead to improved access to cervical cancer ser-
vices for HIV positive women in Zambia.
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